Cart
sales@molnova.com
RAF265
CAS No. 927880-90-8
RAF265( CHIR-265 | RAF 265 | RAF-265 | CHIR265 )
Catalog No. M16644 CAS No. 927880-90-8
A potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 96 | In Stock |
|
| 2MG | 54 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 143 | In Stock |
|
| 25MG | 266 | In Stock |
|
| 50MG | 426 | In Stock |
|
| 100MG | 626 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRAF265
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation.
-
DescriptionA potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation; blocks Raf-MEK-ERK signalling and significantly enhances TRAIL sensitivity in NCI-H727 and CM insulinoma cells; inhibits cell proliferation with IC50 of 0.83-5.54 uM in CRC cells, demonstrates significant anti-tumor activity in tumors of xenograft models.Skin Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsCHIR-265 | RAF 265 | RAF-265 | CHIR265
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorB-Raf| VEGFR2
-
Research AreaCancer
-
IndicationSkin Cancer
Chemical Information
-
CAS Number927880-90-8
-
Formula Weight518.4139
-
Molecular FormulaC24H16F6N6O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 26 mg/mL
-
SMILESFC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F
-
Chemical Name1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mordant P, et al. Mol Cancer Ther. 2010 Feb;9(2):358-68.
2. Zitzmann K, et al. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85.
3. Su Y, et al. Clin Cancer Res. 2012 Apr 15;18(8):2184-98.
4. Chen J, et al .Cancer Res. 2011 Jun 15;71(12):4280-91.
molnova catalog
related products
-
CCT241161
CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF.
-
NST-628
NST-628 is a pan-RAF-MEK molecular glue that prevents RAF from phosphorylating and activating MEK, inhibiting the RAF-MEK signaling complex.
-
I-37 free base( 2359...
I-37 free base is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
